Salk researchers have discovered, for the first time, how to place DNA in specific locations in non-dividing cells
Salk Institute researchers have discovered a holy grail of gene editing—the ability to, for the first time, insert DNA at a target location into the non-dividing cells that make up the majority of adult organs and tissues. The technique, which the team showed was able to partially restore visual responses in blind rodents, will open new avenues for basic research and a variety of treatments, such as for retinal, heart and neurological diseases.
“We are very excited by the technology we discovered because it’s something that could not be done before,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the paper published on November 16, 2016 in Nature. “For the first time, we can enter into cells that do not divide and modify the DNA at will. The possible applications of this discovery are vast.”
Until now, techniques that modify DNA—such as the CRISPR-Cas9 system—have been most effective in dividing cells, such as those in skin or the gut, using the cells’ normal copying mechanisms. The new Salk technology is ten times more efficient than other methods at incorporating new DNA into cultures of dividing cells, making it a promising tool for both research and medicine. But, more importantly, the Salk technique represents the first time scientists have managed to insert a new gene into a precise DNA location in adult cells that no longer divide, such as those of the eye, brain, pancreas or heart, offering new possibilities for therapeutic applications in these cells.
To achieve this, the Salk researchers targeted a DNA-repair cellular pathway called NHEJ (for “non-homologous end-joining”), which repairs routine DNA breaks by rejoining the original strand ends. They paired this process with existing gene-editing technology to successfully place new DNA into a precise location in non-dividing cells.
“Using this NHEJ pathway to insert entirely new DNA is revolutionary for editing the genome in live adult organisms,” says Keiichiro Suzuki, a senior research associate in the Izpisua Belmonte lab and one of the paper’s lead authors. “No one has done this before.”
First, the Salk team worked on optimizing the NHEJ machinery for use with the CRISPR-Cas9 system, which allows DNA to be inserted at very precise locations within the genome. The team created a custom insertion package made up of a nucleic acid cocktail, which they call HITI, or homology-independent targeted integration. Then they used an inert virus to deliver HITI’s package of genetic instructions to neurons derived from human embryonic stem cells.
“That was the first indication that HITI might work in non-dividing cells,” says Jun Wu, staff scientist and co-lead author. With that feat under their belts, the team then successfully delivered the construct to the brains of adult mice. Finally, to explore the possibility of using HITI for gene-replacement therapy, the team tested the technique on a rat model for retinitis pigmentosa, an inherited retinal degeneration condition that causes blindness in humans. This time, the team used HITI to deliver to the eyes of 3-week-old rats a functional copy of Mertk, one of the genes that is damaged in retinitis pigmentosa. Analysis performed when the rats were 8 weeks old showed that the animals were able to respond to light, and passed several tests indicating healing in their retinal cells.
“We were able to improve the vision of these blind rats,” says co-lead author Reyna Hernandez-Benitez, a Salk research associate. “This early success suggests that this technology is very promising.”
The team’s next steps will be to improve the delivery efficiency of the HITI construct. As with all genome editing technologies, getting enough cells to incorporate the new DNA is a challenge. The beauty of HITI technology is that it is adaptable to any targeted genome engineering system, not just CRISPR-Cas9. Thus, as the safety and efficiency of these systems improve, so too will the usefulness of HITI.
“We now have a technology that allows us to modify the DNA of non-dividing cells, to fix broken genes in the brain, heart and liver,” says Izpisua Belmonte. “It allows us for the first time to be able to dream of curing diseases that we couldn’t before, which is exciting.”
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Report: Location of Chinese scientist who says he created first gene-edited babies unknownon November 30, 2019 at 3:20 pm
He Jiankui at the 2018 International Summit on Human Genome Editing in Hong Kong. Photo: Anthony Wallace/AFP via Getty Images The whereabouts of scientist He Jiankui, who claimed to successfully use ...
- 1 year later, mystery surrounds China’s gene-edited babieson November 30, 2019 at 3:18 pm
He has not been seen publicly since January, his work has not been published and nothing is known about the health of the babies. ‘‘That’s the story — it’s all cloaked in secrecy, which is not ...
- Mark Buchanan: Gene editing might alter our DNA. It might destroy our humanity tooon November 30, 2019 at 1:00 am
Biologists recently revealed a new form of the gene-editing tool known as CRISPR that allows researchers to make precise changes to almost any element of DNA, permanently altering cellular ...
- CRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two locion November 29, 2019 at 2:21 am
Furthermore, we design sequential CRISPR-Switch-based editing of two loci in a strictly programmable manner and determined the order of mutagenic events that leads to development of glioblastoma in ...
- Gene editing kills malaria carrying mosquitoeson November 28, 2019 at 2:45 am
Researchers in England wipe out a population of malaria carrying mosquitoes in a laboratory using gene editing, raising renewed hopes of eradicating the disease in the wild. Stuart McDill reports.
- Mystery still surrounds gene-edited babies and Rice connectionon November 27, 2019 at 5:46 pm
“Nothing has changed,“ said Dr. Kiran Musunuru, a University of Pennsylvania geneticist who just published a book about gene editing and the CRISPR babies case. “I think we’re farther from governing ...
- High efficacy full allelic CRISPR/Cas9 gene editing in tetraploid potatoon November 27, 2019 at 3:26 am
Highly increased editing efficiencies in the Granular Bound Starch Synthase gene at the protoplast level were obtained by replacement of the Arabidopsis U6 promotor, driving expression of the CRISPR ...
- Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now?on November 26, 2019 at 12:35 pm
CRISPR Therapeutics (NASDAQ:CRSP) made news recently after unveiling some impressive results for its signature gene-editing drug, CTX001. Coupled with an earlier analyst upgrade from Oppenheimer, the ...
- Genomics ETFs Surge on CRISPR's Gene Editing Progresson November 26, 2019 at 7:51 am
Notably, the studies were evaluating the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders — sickle cell disease (SCD) and adult transfusion-dependent b-thalassemia (TDT). CRISPR ...
via Bing News